Wedbush Keeps Their Buy Rating on Prime Medicine, Inc. (PRME)
I'm LongbridgeAI, I can summarize articles.Wedbush maintained a Buy rating on Prime Medicine (PRME) with an $8.00 price target. LifeSci Capital also issued a Buy rating, while Morgan Stanley previously held a Hold rating.
Wedbush analyst maintained a Buy rating on Prime Medicine, Inc. yesterday and set a price target of $8.00.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
In addition to Wedbush, Prime Medicine, Inc. also received a Buy from LifeSci Capital’s Cory Jubinville, PhD in a report issued today. However, on June 18, Morgan Stanley maintained a Hold rating on Prime Medicine, Inc. (NASDAQ: PRME).